Cipla Announces Q3 FY1516 Unaudited Consolidated Financial Results
Mumbai, India, 10th Feb 2016: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited
Consolidated Financial Results for the quarter ended Dec 31, 2015 (Q3).
Key Financial & Performance Highlights Q3 FY1516 vis-a-vis Q3 FY1415:
(Current year figures include the relevant results of Cipla’s subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).
• Income from operations grew by 12.3% to Rs. 3,107 cr, up from Rs. 2,765 cr
• EBITDA decreased by 18.1% to Rs. 454 cr, down from Rs. 554 cr
• Profit after tax increased by 4.7% to Rs. 343 cr, up from Rs. 328 cr
Profit & Loss Highlights:
• Material cost is at 39.7% of income from operations in Q3 FY1516 as compared to 35.8% in Q3 FY1415
• EBIDTA as % of income from operations decreased to 14.6% in Q3 FY1516 from 20% in Q3 FY1415
• Profit after tax increased by 4.7% to Rs. 343 cr, up from Rs. 328 cr in Q3 FY1415
Performance Review:
Domestic business:
• Domestic sales reduced by 0.4% to Rs. 1,194 cr during Q3 FY1516 from Rs. 1,199 cr during Q3 FY1415
International business:
• Exports of formulations increased by 32.5% to Rs. 1,690 cr during Q3 FY1516, from Rs. 1,275 cr during Q3 FY1415
• Exports of APIs decreased by 5.3% to Rs. 143 cr during Q3 FY1516, from Rs. 151 cr during Q3 FY1415
About Cipla:
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.
Cipla’s research and development focuses on developing innovative products and drug delivery systems.
Media Contacts:
Investor Relations
Anant Atal
Contact No.: 022 – 24826450
E-Mail: anant.atal@cipla.com
Corporate Communications
Pallavi Golar
Contact No.: +91 9833641788
E-Mail: pallavi.golar@cipla.com
Key Financial & Performance Highlights Q3 FY1516 vis-a-vis Q3 FY1415:
(Current year figures include the relevant results of Cipla’s subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).
• Income from operations grew by 12.3% to Rs. 3,107 cr, up from Rs. 2,765 cr
• EBITDA decreased by 18.1% to Rs. 454 cr, down from Rs. 554 cr
• Profit after tax increased by 4.7% to Rs. 343 cr, up from Rs. 328 cr
Profit & Loss Highlights:
• Material cost is at 39.7% of income from operations in Q3 FY1516 as compared to 35.8% in Q3 FY1415
• EBIDTA as % of income from operations decreased to 14.6% in Q3 FY1516 from 20% in Q3 FY1415
• Profit after tax increased by 4.7% to Rs. 343 cr, up from Rs. 328 cr in Q3 FY1415
Performance Review:
Domestic business:
• Domestic sales reduced by 0.4% to Rs. 1,194 cr during Q3 FY1516 from Rs. 1,199 cr during Q3 FY1415
International business:
• Exports of formulations increased by 32.5% to Rs. 1,690 cr during Q3 FY1516, from Rs. 1,275 cr during Q3 FY1415
• Exports of APIs decreased by 5.3% to Rs. 143 cr during Q3 FY1516, from Rs. 151 cr during Q3 FY1415
About Cipla:
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.
Cipla’s research and development focuses on developing innovative products and drug delivery systems.
Media Contacts:
Investor Relations
Anant Atal
Contact No.: 022 – 24826450
E-Mail: anant.atal@cipla.com
Corporate Communications
Pallavi Golar
Contact No.: +91 9833641788
E-Mail: pallavi.golar@cipla.com